Last checked at 12 Apr 2021 13:40
Ap19
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
1. KEY INFORMATION
| Name of person dealing (Note 1) | Barclays PLC. | |
| Company dealt in | WILLIS TOWERS WATSON PLC | |
| Class of relevant security to which the | ORD | |
| dealings being disclosed relate (Note 2) | ||
| Date of dealing | 09 April 2021 |
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
| Class of relevant security: | ORD | ||||
| Long | Short | ||||
| Number | (%) | Number | (%) | ||
(1) | Relevant securities | ||||
1,674,769 | 1.30% | 190,397 | 0.15% | ||
|
|
|
| ||
(2) | Derivatives (other than options): |
|
|
|
|
102,359 | 0.08% | 7,100 | 0.01% | ||
|
|
|
| ||
(3) | Options and agreements to |
|
|
|
|
| purchase/sell: | 6,100 | 0.00% | 6,100 | 0.00% | |
|
|
|
| ||
| TOTAL: |
|
|
|
| |
1,783,228 | 1.38% | 203,597 | 0.16% | ||
(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)
Class of relevant security: | Long | Short | ||||
| Number |
| (%) | Number |
| (%) |
(1) Relevant securities |
|
| ||||
(2) Derivatives (other than options) |
|
| ||||
(3) Options and agreements to purchase/sell |
|
| ||||
Total |
|
| ||||
| ||||||
Ap20
1. DEALINGS (Note 4)
(a) Purchases and sales
| Purchase/sale | Number of relevant securities | Price per unit |
Purchase | 5 | 238.8900 USD |
Purchase | 18 | 238.9700 USD |
Purchase | 27 | 239.4400 USD |
Purchase | 33 | 239.4500 USD |
Purchase | 36 | 237.2280 USD |
Purchase | 40 | 239.3900 USD |
Purchase | 43 | 239.9000 USD |
Purchase | 100 | 238.8100 USD |
Purchase | 100 | 237.6100 USD |
Purchase | 150 | 239.3816 USD |
Purchase | 171 | 239.2194 USD |
Purchase | 200 | 238.6450 USD |
Purchase | 632 | 238.0700 USD |
Purchase | 953 | 239.2677 USD |
Purchase | 2,507 | 238.9603 USD |
Purchase | 2,980 | 239.4197 USD |
Purchase | 3,276 | 239.1303 USD |
Purchase | 3,457 | 239.1485 USD |
Purchase | 5,702 | 238.9753 USD |
Purchase | 6,851 | 239.8577 USD |
Purchase | 9,193 | 239.3118 USD |
Purchase | 12,822 | 239.9800 USD |
Sale | 6 | 239.1000 USD |
Sale | 6 | 239.0600 USD |
Sale | 6 | 239.1850 USD |
Sale | 12 | 239.5475 USD |
Sale | 18 | 239.1133 USD |
Sale | 20 | 239.5140 USD |
Sale | 30 | 239.1110 USD |
Sale | 36 | 239.0050 USD |
Sale | 39 | 239.9600 USD |
Sale | 50 | 239.2850 USD |
Sale | 54 | 237.2280 USD |
Sale | 100 | 238.9100 USD |
Sale | 100 | 238.4800 USD |
Sale | 100 | 237.6600 USD |
Sale | 100 | 238.9300 USD |
Sale | 100 | 239.8700 USD |
Sale | 105 | 238.8900 USD |
Sale | 140 | 239.0400 USD |
Sale | 159 | 238.9574 USD |
Sale | 185 | 239.1197 USD |
Sale | 200 | 238.0700 USD |
Sale | 300 | 239.8833 USD |
Sale | 300 | 239.3813 USD |
Sale | 303 | 239.9686 USD |
Sale | 500 | 238.9907 USD |
Sale | 500 | 239.1680 USD |
Sale | 746 | 239.5893 USD |
Sale | 1,055 | 239.3201 USD |
Sale | 1,100 | 238.4836 USD |
Sale | 1,176 | 239.5855 USD |
Sale | 1,299 | 238.9459 USD |
Sale | 1,848 | 238.8966 USD |
Sale | 2,414 | 239.0766 USD |
Sale | 2,776 | 239.1235 USD |
Sale | 4,323 | 239.0935 USD |
Sale | 4,741 | 239.5782 USD |
Sale | 5,655 | 239.0961 USD |
Sale | 6,851 | 239.8577 USD |
Sale | 11,843 | 239.9800 USD |
(b) Derivatives transactions (other than options transactions)
Product name, e.g. CFD | Nature of transaction (Note 6) | Number of relevant securities (Note 7) | Price per unit (Note 5) |
|
|
|
|
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name, e.g. call option | Writing, selling, purchasing, varying etc. | Number of securities to which the option relates (Note 7) | Exercise price | Type, e.g. American, European etc. | Expiry date | Option money paid/received per unit (Note 5) |
|
|
|
|
|
|
|
(ii) Exercising
Product name, e.g. call option | Number of securities | Exercise price per unit (Note 5) |
|
|
|
(d) Other dealings (including transactions in respect of new securities) (Note 4)
Nature of transaction (Note 8) | Details | Price per unit (if applicable) (Note 5) |
|
|
|
Ap21
2. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
None
| Is a Supplemental Form 8 (Open Positions) attached? | YES |
| Date of disclosure: | 12 Apr 2021 |
| Contact name: | Large Holdings Regulatory Operations |
| Telephone number: | 020 3134 7213 |
| If a connected EFM, name of offeree/offeror with which connected | |
| If a connected EFM, state nature of connection |
Ap23
SUPPLEMENTAL FORM 8
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.1 AND RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DETAILS OF OPEN POSITIONS
(This form should be attached to Form 8.1(a) & (b)(i), Form 8.1(b)(ii) or Form 8.3, as appropriate)
OPEN POSITIONS (Note 1)
| Product name | Written or | Number of | Exercise | Type | Expiry |
| purchased | relevant securities | price | date | ||
| to which the option | |||||
| or derivative | |||||
| relates | |||||
Put Options | Purchased | -100 | 220.0000 | American | Jul 16, 2021 |
Call Options | Purchased | 100 | 240.0000 | American | Jul 16, 2021 |
Call Options | Purchased | 6,000 | 220.0000 | American | Jul 16, 2021 |
Put Options | Purchased | -6,000 | 200.0000 | American | Jul 16, 2021 |
Notes
1. Where there are open option positions or open derivative positions (except for CFDs), full details should be given. Full details of any existing agreements to purchase or to sell must also be given on this form.
2. For all prices and other monetary amounts, the currency must be stated.
For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210412005548/en/
Copyright Business Wire 2021